
               
               
               7	DRUG INTERACTIONS
               
               
                  
                     
                        
                           CNS depressants: Increased risk of respiratory depression, hypotension, profound sedation, coma or death. When combined therapy with CNS depressant is contemplated, the dose of one or both agents should be reduced. ( )
                                        7.2
                           
                           Mixed agonist/antagonist opioids (i.e., pentazocine, nalbuphine, and butorphanol): May reduce analgesic effect and/or precipitate withdrawal symptoms. ( )
                                        7.3
                           
                           Cimetidine: Combination use may precipitate confusion, disorientation, respiratory depression, apnea, seizures. ( )
                                        7.4
                           
                           Anticholinergics: May result in urinary retention and/or severe constipation, which may lead to paralytic ileus. ( )
                                        7.5
                           
                           Monoamine oxidase inhibitors (MAOIs): Potentiate the action of opioids. OPANA ER should not be used in patients taking MAOIs or within 14 days of stopping such treatment. ( )
                                        7.6
                           
                           Dose adjustment for CYP3A450 or 2C9-mediated drug-drug interactions is not required. ( )
                                        7.1
                           
                        
                     
                  
               
            
         